A detailed history of Rafferty Asset Management, LLC transactions in Astria Therapeutics, Inc. stock. As of the latest transaction made, Rafferty Asset Management, LLC holds 53,381 shares of ATXS stock, worth $502,849. This represents 0.0% of its overall portfolio holdings.

Number of Shares
53,381
Previous 109,826 51.39%
Holding current value
$502,849
Previous $999,000 41.24%
% of portfolio
0.0%
Previous 0.0%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$8.97 - $12.65 $506,311 - $714,029
-56,445 Reduced 51.39%
53,381 $587,000
Q2 2024

Aug 13, 2024

SELL
$8.83 - $13.51 $412,387 - $630,957
-46,703 Reduced 29.84%
109,826 $999,000
Q1 2024

May 13, 2024

BUY
$6.99 - $16.69 $1.09 Million - $2.61 Million
156,529 New
156,529 $2.2 Million

Others Institutions Holding ATXS

About Astria Therapeutics, Inc.


  • Ticker ATXS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 15,178,000
  • Market Cap $143M
  • Description
  • Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage...
More about ATXS
Track This Portfolio

Track Rafferty Asset Management, LLC Portfolio

Follow Rafferty Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rafferty Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Rafferty Asset Management, LLC with notifications on news.